Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:brand |
gptkb:Pemazyre
|
| gptkbp:CASNumber |
1513858-77-6
|
| gptkbp:contraindication |
hypersensitivity to pemigatinib
|
| gptkbp:developer |
gptkb:Incyte_Corporation
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
15.4 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C24H27F2N5O4
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=NC(=C(N=C21)N)C3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)NCCOCCO
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pemigatinib
|
| gptkbp:indication |
relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:molecularWeight |
483.5 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:pregnancyWarning |
may cause fetal harm
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71681573 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
abdominal pain constipation fatigue alopecia dry mouth arthralgia dysgeusia hyperphosphatemia nail toxicity stomatitis dry eye serous retinal detachment |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR2 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
cholangiocarcinoma
myeloid/lymphoid neoplasms with FGFR1 rearrangement |
| gptkbp:bfsParent |
gptkb:CD332
|
| gptkbp:bfsLayer |
7
|